PeptideJournal
Research18 min read

Peptide Vaccines: Next-Generation Immunotherapy

For decades, vaccines have been built around weakened or killed pathogens — whole organisms presented to the immune system so it can learn to fight them.

For decades, vaccines have been built around weakened or killed pathogens — whole organisms presented to the immune system so it can learn to fight them. That approach works, but it carries baggage: side effects from unnecessary components, complex manufacturing, cold-chain storage requirements, and limited ability to target specific threats like individual tumors. Peptide vaccines take a fundamentally different approach. Instead of throwing the entire pathogen at your immune system, they use carefully selected protein fragments — epitopes — to trigger a precise, targeted immune response.

The idea is not new. Researchers have been exploring peptide-based vaccines since the 1990s. What is new: the tools to make them work. Advances in genomic sequencing, computational epitope prediction, nanoparticle delivery, and combination immunotherapy have pushed peptide vaccines from a promising-but-underperforming concept into one of the most active areas in modern medicine. More than 30 peptide vaccine candidates reached Phase II clinical trials by mid-2025, a record for the field. And with personalized neoantigen vaccines showing real survival benefits in melanoma and pancreatic cancer, the gap between promise and proof is finally narrowing.

This article breaks down where peptide vaccine research stands today — from cancer immunotherapy to infectious diseases — and what the science actually shows.

Table of Contents

How Peptide Vaccines Work

Traditional vaccines expose the immune system to large, complex antigens — sometimes entire inactivated viruses. Your immune system responds broadly, generating antibodies and T cells against many parts of the pathogen. It works, but it's imprecise.

Peptide vaccines strip away everything except the essential recognition signals. A typical peptide vaccine contains one or more short amino acid sequences (usually 8-30 amino acids long) that correspond to specific epitopes — the molecular fingerprints that T cells and B cells use to identify threats.

Here's the basic mechanism:

  1. Peptides are administered (usually via injection) along with an adjuvant — a substance that amplifies the immune response.
  2. Antigen-presenting cells (APCs), primarily dendritic cells, pick up the peptides and display them on their surface using MHC (major histocompatibility complex) molecules.
  3. T cells recognize the peptide-MHC complex. CD8+ cytotoxic T cells are activated to kill cells displaying that peptide (like cancer cells or virus-infected cells), while CD4+ helper T cells coordinate the broader immune response.
  4. Memory T cells form, providing long-lasting protection against future encounters with the same target.

The advantage over traditional vaccines is specificity. Because you're selecting exactly which molecular targets the immune system should attack, you can direct the response with surgical precision — particularly valuable in cancer, where you want to destroy tumor cells while leaving healthy tissue alone.

The downside? Peptides alone tend to be poor immunogens. Short peptide sequences are rapidly cleared from the body, and without the "danger signals" that come with a whole pathogen, the immune response can be weak. This is why delivery systems and adjuvants matter so much, and why early peptide vaccine trials often disappointed.

Peptide Vaccines in Cancer Immunotherapy

Cancer has become the primary proving ground for peptide vaccines. The logic is straightforward: tumors express abnormal proteins on their surface. If you can identify those proteins, synthesize the relevant peptide epitopes, and vaccinate a patient with them, you might train their immune system to recognize and destroy the cancer.

Two broad categories of tumor antigens have driven this work:

Tumor-associated antigens (TAAs) are proteins that are overexpressed in cancer cells but also present at lower levels in normal tissue. HER2 in breast cancer is the classic example. Vaccines targeting TAAs have been the most extensively tested, though the immune system's natural tolerance to these self-proteins makes them challenging targets.

Tumor-specific antigens (neoantigens) arise from mutations unique to an individual's cancer. Because these proteins don't exist in normal tissue, the immune system hasn't learned to tolerate them — making them ideal vaccine targets. The catch is that every patient's neoantigens are different, requiring personalized vaccine design.

Since 2015, at least 66 clinical trials have been initiated to test peptide-based cancer vaccines, according to ClinicalTrials.gov registrations. The cancers most frequently targeted include melanoma, breast cancer, glioma, lung cancer, ovarian cancer, colorectal cancer, and pancreatic cancer [1].

Only one cancer vaccine with a peptide-related mechanism has ever received FDA approval: sipuleucel-T (Provenge), approved in April 2010 for metastatic castration-resistant prostate cancer. Sipuleucel-T uses the patient's own dendritic cells, which are exposed to a fusion protein containing prostatic acid phosphatase (PAP) and GM-CSF. In the pivotal IMPACT trial of 512 patients, it extended median overall survival by 4.1 months (25.8 vs. 21.7 months), with a 22% reduction in the risk of death [2]. While technically a cell-based immunotherapy rather than a pure peptide vaccine, it demonstrated the principle that targeted immune stimulation against specific protein epitopes can produce meaningful clinical outcomes.

For a broader look at immune-related peptide research, see our guide on best peptides for immune support and our overview of peptides for cancer research.

Personalized Neoantigen Vaccines: The Cutting Edge

The most exciting development in peptide vaccines isn't a single drug — it's a paradigm. Personalized neoantigen vaccines are designed from scratch for each individual patient based on the unique mutations in their tumor.

The process typically works like this:

  1. Tumor sequencing: A biopsy is analyzed using whole-exome sequencing (WES) and RNA sequencing to identify somatic mutations.
  2. Neoantigen prediction: Computational algorithms predict which mutated peptides are most likely to bind MHC molecules and trigger T cell responses.
  3. Vaccine synthesis: The selected neoantigen peptides are manufactured — either as synthetic peptides or encoded in mRNA.
  4. Vaccination: The patient receives the personalized vaccine, often alongside immune checkpoint inhibitors.

This approach sidesteps one of the biggest problems with traditional peptide cancer vaccines: immune tolerance. Because neoantigens are truly foreign to the body — they've never existed in healthy tissue — the immune system can mount a strong response without the brakes that normally prevent attacks on self-proteins.

The personalized cancer vaccine clinical pipeline is growing fast. As of 2025, peptide vaccines account for roughly 40% of all personalized cancer vaccine trials, with the United States (44%) and China (24%) hosting the majority of studies [3]. Phase I trials still dominate — over 90% of the total — but several programs have advanced to Phase II and III.

Key Clinical Trials and Results

Melanoma: NeoVax and mRNA-4157

The NeoVax trial, published in Cell in 2025, tested a multi-adjuvant personalized neoantigen peptide vaccine in melanoma patients. Researchers at the Dana-Farber Cancer Institute formulated personalized peptide vaccines with poly-ICLC and Montanide adjuvants, administered alongside ipilimumab and nivolumab checkpoint inhibitors. All nine fully vaccinated patients generated T cell responses against the majority of immunizing neoepitopes, with six of nine showing measurable CD8+ T cell responses detectable directly from blood samples [4].

The mRNA-4157/V940 trial (KEYNOTE-942) took a related but different approach, encoding personalized neoantigens in mRNA rather than synthetic peptides. In this randomized Phase IIb study, combining the Moderna/Merck vaccine with pembrolizumab reduced melanoma recurrence by 44% compared to pembrolizumab alone (HR 0.561). At 18 months, recurrence-free survival was 79% in the combination group. Extended three-year follow-up data confirmed sustained benefit, catalyzing a global Phase III expansion with regulatory submissions expected in 2026 [5].

A separate 20-year follow-up analysis of the Mel39 multipeptide melanoma vaccine trial (NCT00938223), published in 2025, tracked 51 patients with resected stage IIB-IV melanoma who received vaccination with either 4 or 12 melanoma peptides. This study provided rare long-term survival data for peptide-vaccinated cancer patients [6].

Pancreatic Cancer: BioNTech's Autogene Cevumeran

Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate below 12%, making any therapeutic advance significant. BioNTech's autogene cevumeran (BNT122), a personalized mRNA-based neoantigen vaccine, produced striking results in a Phase I trial with three-year follow-up data.

Of 16 patients who received the vaccine after surgery, 8 developed strong T cell responses against the encoded neoantigens — with 98% of those T cells being entirely new responses not present before vaccination. The persistence was remarkable: over 80% of vaccine-induced neoantigen-specific T cells were still detectable three years after administration. Of the 8 immune responders, 6 remained disease-free at three years. In contrast, 7 of 8 non-responders experienced tumor recurrence [7].

Autogene cevumeran is now being evaluated in three randomized Phase II trials across PDAC, melanoma, and colorectal cancer.

A separate personalized peptide neoantigen vaccine study presented at ASCO 2024 reported a 3-year recurrence-free survival rate of 56% and 3-year overall survival of 74% in vaccinated pancreatic cancer patients. Single-cell sequencing revealed CD8+ cytotoxic T cells expanding during the priming phase with a high proportion (average 38.4%) showing persistent expansion lasting 2.8 to 21.8 months [8].

Brain Cancer: The H3K27M Glioma Vaccine

Diffuse midline gliomas carrying the H3K27M mutation are among the most lethal brain cancers, with median survival often measured in months. A first-in-human compassionate use study, published in Nature Medicine in 2023, tested a 27-amino-acid long peptide vaccine (H3K27M-vac) targeting this specific driver mutation in eight adults.

Five of eight patients mounted mutation-specific immune responses, dominated by CD4+ T cells. One patient achieved complete remission lasting more than 31 months — extraordinary for this disease. Median progression-free survival was 6.2 months, and median overall survival was 12.8 months [9].

What made this vaccine unusual: it worked across multiple HLA types. Most peptide vaccines require patients to carry specific HLA alleles (the genes that determine which peptides your immune system can present). The H3K27M vaccine induced responses regardless of HLA type, broadening its potential patient population. A deeper immune analysis of the patient who achieved complete remission, published in Science Advances in 2024, confirmed robust T and B cell responses across diverse HLA loci [10].

The multicenter INTERCEPT-H3 Phase I trial (NCT04808245) is now testing this vaccine in newly diagnosed midline glioma patients in combination with radiotherapy and the anti-PD-L1 antibody atezolizumab.

Breast Cancer: Mixed Results

Breast cancer peptide vaccine trials tell a cautionary story. Nelipepimut-S (NeuVax), targeting the HER2-derived E75 peptide, showed a roughly 50% reduction in recurrence risk in Phase I/II trials, with a 5-year disease-free survival of 94.6% in optimally dosed patients versus 80.2% in unvaccinated controls [11].

But the Phase III PRESENT trial told a different story. Among 758 patients with HER2 low-expressing, node-positive breast cancer, nelipepimut-S showed no significant difference in disease-free survival compared to placebo at 16.8 months of follow-up. The trial was stopped for futility [12].

A second HER2 peptide, GP2 (GLSI-100), showed a more promising signal. In Phase II, HER2-positive patients who completed the full vaccine series had 100% disease-free survival at 5 years versus 89% for controls (p = 0.08) — not statistically significant, but enough to warrant a Phase III trial. The FLAMINGO-01 Phase III trial is now enrolling approximately 500 patients, and GLSI-100 received FDA Fast Track designation in September 2025 [13].

TrialCancer TypePhaseKey ResultStatus
NeoVaxMelanomaIT cell responses in 9/9 patientsPublished 2025
mRNA-4157/V940MelanomaIIb44% reduction in recurrencePhase III ongoing
Autogene CevumeranPancreaticI6/8 responders disease-free at 3 yearsPhase II ongoing
H3K27M-vacGliomaI (compassionate)Complete remission in 1/8, 31+ monthsPhase I trial ongoing
Nelipepimut-SBreast (HER2)IIINo DFS benefit vs. placeboStopped for futility
GP2 (GLSI-100)Breast (HER2)III100% DFS in HER2+ subgroup (Phase II)Phase III enrolling

Peptide Vaccines for Infectious Diseases

While cancer dominates peptide vaccine research, infectious diseases remain an important application — particularly for pathogens where traditional vaccines have failed or where rapid adaptability is needed.

Influenza

The holy grail of flu vaccination is a "universal" vaccine that works across multiple strains and seasons, eliminating the annual guessing game of strain selection. Peptide vaccines are natural candidates because they can target conserved epitopes shared across influenza A and B strains.

BiondVax's Multimeric-001 (M-001) was the most clinically advanced candidate, containing conserved B and T cell epitopes from hemagglutinin, nucleoprotein, and matrix proteins. It completed six Phase I/II trials showing safety and immunogenicity in 698 participants before advancing to a pivotal Phase III trial across seven countries. Unfortunately, the Phase III trial, with results announced in October 2020, failed to meet its primary or secondary efficacy endpoints, showing no statistically significant reduction in flu illness or severity compared to placebo [14].

Flu-v, another peptide-based influenza vaccine using T cell epitopes identified through computational methods, has progressed through Phase II trials with promising immunogenicity data.

SARS-CoV-2

The COVID-19 pandemic generated significant interest in peptide-based approaches. CoVac-1, developed at the University of Tubingen, contained SARS-CoV-2 T cell epitopes from six different viral proteins (spike, nucleocapsid, membrane, envelope, and ORF8) combined with a TLR1/2 agonist adjuvant. Phase I results published in Nature in 2021 showed T cell responses in all 36 participants — responses that exceeded those seen after natural infection and after vaccination with approved mRNA vaccines. These responses were unaffected by variants of concern [15].

A subsequent Phase I/II trial in 54 patients with B-cell deficiency (primarily cancer-related) found that 86% developed SARS-CoV-2-specific T cell responses despite their inability to generate antibodies — a finding with clear implications for immunocompromised populations [16]. CoVac-1-induced T cells remained detectable 12 months after a single dose.

Russia's EpiVacCorona, a peptide-based COVID vaccine, was authorized for use in December 2020, though it faced criticism over its peptide selection methodology and real-world immunogenicity.

Malaria and Other Targets

Peptide vaccines for malaria have focused on the circumsporozoite (CS) protein of Plasmodium falciparum. Self-assembling peptide nanoparticles (SAPNs) incorporating the NANP repeat B cell epitope and predicted CD8+ T cell epitopes have shown promise in preclinical models. UK-39, a cyclized peptide conjugated to immunopotentiating influenza virosomes, advanced to clinical evaluation as an alternative delivery platform [17].

For more on how peptides interact with infectious organisms, see our article on antimicrobial peptides research and our LL-37 research profile.

Delivery Systems and Adjuvants

The biggest technical hurdle for peptide vaccines isn't identifying the right targets — it's getting those targets to the immune system effectively. Free peptides injected subcutaneously are rapidly degraded by proteases, poorly taken up by dendritic cells, and generally produce weak immune responses. The solution lies in advanced delivery systems and adjuvants.

Self-Assembling Peptide Nanoparticles

One of the most active areas of research involves peptides that spontaneously form nanostructures. Beta-sheet-forming peptides like FKFE8, RADA16, and EAK16-II assemble into nanofibers and nanotubes with properties that naturally stimulate immune responses — a phenomenon called "self-adjuvanting." A 2025 review in Vaccines highlighted how these ordered nanoarchitectures activate the innate immune system without requiring traditional adjuvants [18].

Researchers at Duke University demonstrated that nanofibers made with D-amino acids (mirror-image forms resistant to enzymatic degradation) could even enable oral immunization — a long-sought goal for vaccine delivery. Adding proline-alanine-serine (PAS) sequences improved the nanofibers' ability to penetrate intestinal mucus [19].

For cancer applications, a 2025 study in Nano Research developed a self-assembling neoantigen nanoparticle vaccine (Neo-NV) integrating charge-modified KRAS G12V-derived peptides with dual adjuvants (CpG oligonucleotides and R848). In melanoma mouse models, Neo-NV promoted dendritic cell maturation, activated both CD4+ and CD8+ T cells, and significantly suppressed tumor growth [20].

Novel Adjuvant Combinations

Traditional aluminum-based adjuvants (alum) primarily drive antibody responses but are weak at inducing the CD8+ T cell responses needed for cancer vaccines. TLR (Toll-like receptor) agonists have emerged as superior partners for peptide vaccines:

  • Poly-ICLC (a TLR3 agonist) is used in the NeoVax melanoma vaccine
  • CpG oligonucleotides (TLR9 agonists) produced 90% protection against lethal H1N1 challenge in a single-dose mouse study when combined with influenza peptide nanoparticles
  • Montanide ISA-51 creates a depot effect, slowly releasing peptides over time
  • XS15 (TLR1/2 agonist) is the adjuvant behind CoVac-1's strong T cell responses

The trend is toward combining multiple adjuvants and delivery strategies. Research on the immune-modulating peptide Thymosin Alpha-1 has informed thinking about how peptide-based immune stimulation can be optimized, while studies on natural immune peptides like defensins have revealed new mechanisms of innate immune activation relevant to vaccine design.

Challenges and Limitations

Despite the progress, peptide vaccines face real obstacles that explain why so few have reached late-stage clinical trials.

HLA restriction. The immune system's ability to present a peptide depends on which HLA alleles a person carries. A peptide that triggers a strong response in someone with HLA-A2 might do nothing in someone with different HLA alleles. This limits the proportion of any population that can benefit from a given peptide vaccine. The H3K27M glioma vaccine's HLA-independent mechanism is notable precisely because it's the exception.

Immune evasion. Tumors are moving targets. Cancer cells can downregulate MHC expression, shed targeted antigens, or create an immunosuppressive microenvironment that neutralizes T cells even after they're activated. This is why combination approaches with checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies are increasingly standard.

Manufacturing complexity for personalized vaccines. Building a vaccine from scratch for each patient takes time and money. Current turnaround from biopsy to vaccine is roughly 4-9 weeks, though AI-driven neoantigen prediction and improved manufacturing are pushing this down. First commercial approvals for personalized cancer vaccines are not expected before 2029.

The Phase III wall. Many peptide vaccines that look promising in Phase I/II trials — with strong immune responses and encouraging survival signals — fail when tested in larger, randomized Phase III trials. Nelipepimut-S and Multimeric-001 both followed this pattern. The field still struggles to translate immunological responses into consistent clinical benefit.

Weak immunogenicity. Even with adjuvants, peptide vaccines tend to produce weaker immune responses than viral-vector or mRNA-based vaccines delivering the same antigens. This is partly why mRNA-based neoantigen vaccines (like mRNA-4157) have advanced faster than pure peptide approaches — the mRNA platform generates sustained antigen expression within the patient's own cells.

Where the Field Is Heading

Several converging trends are reshaping peptide vaccine research:

AI-driven epitope prediction. Machine learning models are becoming far better at predicting which neoantigens will actually trigger immune responses — a task where traditional algorithms had high false-positive rates. In 2024, a foundation model called HydrogelFinder was developed specifically for rational design of self-assembling peptides, using AI to explore chemical space beyond conventional peptide structures [21].

Combination with checkpoint inhibitors. The synergy between peptide vaccines and checkpoint inhibitors is now the dominant clinical strategy. Vaccines prime the immune system against specific targets; checkpoint inhibitors remove the brakes that tumors use to shut down the immune response. The KEYNOTE-942 data showing 44% recurrence reduction with mRNA-4157 plus pembrolizumab is the clearest proof of concept to date.

Non-canonical antigen targets. Genomic and immunopeptidomic analyses have uncovered peptides from regions of the genome previously thought to be non-coding — so-called "cryptic" or "dark matter" antigens. These peptides are often absent from healthy tissue but enriched in tumors, and because they're non-mutated, they may be shared across patients, enabling off-the-shelf rather than personalized vaccines [22].

Peptide-based immune checkpoint inhibitors. Beyond vaccines, peptides are being developed as alternatives to the monoclonal antibodies that currently dominate checkpoint immunotherapy. Bristol-Myers Squibb developed BMS-986189, a macrocyclic peptide targeting PD-L1 with picomolar binding affinity — comparable to antibodies but at a fraction of the manufacturing cost. While the first-generation compound's development was suspended, next-generation compounds like BMS-986238 are advancing [23].

Multi-pathogen and universal vaccines. Computational design of multi-epitope vaccines targeting conserved regions across multiple pathogens is an active research area. One 2025 study designed a universal vaccine combining SARS-CoV-2 nucleocapsid epitopes with influenza M2e and HA2 segments into a single multi-epitope construct — a platform approach that could fundamentally change how we prepare for pandemics [24].

The Bottom Line

Peptide vaccines represent one of the most precise tools in the immunotherapy arsenal. By targeting specific molecular signatures on cancer cells or pathogens, they offer the theoretical promise of strong, targeted immune responses with minimal collateral damage.

The reality has been more complicated. Decades of clinical trials have taught researchers that peptides alone are weak immunogens, that HLA restriction limits patient populations, and that immunological responses don't always translate into clinical benefit. The Phase III failures of nelipepimut-S in breast cancer and Multimeric-001 in influenza are sobering reminders.

But the tide is turning. Personalized neoantigen vaccines — whether peptide-based or mRNA-encoded — are producing durable immune responses and real survival benefits in some of the hardest-to-treat cancers. The BioNTech pancreatic cancer data, with immune responders remaining disease-free three years after vaccination, would have been unthinkable a decade ago. Self-assembling peptide nanoparticles are solving the delivery problem. AI is accelerating epitope prediction. And combination with checkpoint inhibitors is unlocking efficacy that peptide vaccines alone never achieved.

The field is not there yet. Most trials remain in Phase I/II, and the first commercial approvals for personalized cancer vaccines likely won't arrive before 2029. But for the first time, peptide vaccines are showing they can do what researchers have long believed they should: teach the immune system to destroy cancer and fight infection with a precision that no other vaccine platform can match.

References

  1. Frontiers in Immunology. "Peptide-based vaccine for cancer therapies." 2023. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1210044/full

  2. Kantoff PW, et al. "Sipuleucel-T immunotherapy for castration-resistant prostate cancer." New England Journal of Medicine. 2010;363(5):411-22. https://pubmed.ncbi.nlm.nih.gov/21471425/

  3. Iamukova A, et al. "Personalized Cancer Vaccines in the Clinical Trial Pipeline." Asia-Pacific Journal of Clinical Oncology. 2025. https://onlinelibrary.wiley.com/doi/10.1111/ajco.70006

  4. "A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma." Cell. 2025. https://www.cell.com/cell/abstract/S0092-8674(25)00685-3

  5. Moderna/Merck. KEYNOTE-942 Phase IIb trial of mRNA-4157 (V940) plus pembrolizumab in melanoma. Extended follow-up data.

  6. "Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma." PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12407048/

  7. BioNTech. "Three-year Phase 1 follow-up data for mRNA-based individualized immunotherapy candidate in resected pancreatic cancer." https://investors.biontech.de/news-releases/news-release-details/three-year-phase-1-follow-data-mrna-based-individualized

  8. "Impact of personalized peptide neoantigen vaccines on immunologic responses in patients with pancreatic cancer." Journal of Clinical Oncology. 2024;42(16_suppl):e16351. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16351

  9. Platten M, et al. "A H3K27M-targeted vaccine in adults with diffuse midline glioma." Nature Medicine. 2023;29:2586-2592. https://www.nature.com/articles/s41591-023-02555-6

  10. "H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient." Science Advances. 2024. https://www.science.org/doi/10.1126/sciadv.adi9091

  11. Peoples GE, et al. "Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients." Annals of Oncology. 2014;25(9):1735-1742. https://pubmed.ncbi.nlm.nih.gov/24907636/

  12. Mittendorf EA, et al. "Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence." Clinical Cancer Research. 2019;25(14):4248-4254. https://aacrjournals.org/clincancerres/article/25/14/4248/81764/

  13. Greenwich LifeSciences. FLAMINGO-01 Phase III trial of GLSI-100 (GP2 + GM-CSF). FDA Fast Track designation September 2025. https://greenwichlifesciences.com/

  14. BiondVax Pharmaceuticals. "Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate." October 2020. https://www.prnewswire.com/il/news-releases/biondvax-announces-topline-results-from-phase-3-clinical-trial-of-the-m-001-universal-influenza-vaccine-candidate-301158876.html

  15. Walz JS, et al. "A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity." Nature. 2021;601:617-622. https://www.nature.com/articles/s41586-021-04232-5

  16. Walz JS, et al. "Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency." Nature Communications. 2023;14:5032. https://www.nature.com/articles/s41467-023-40758-0

  17. "Peptides for Vaccine Development." ACS Applied Bio Materials. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9384901/

  18. "Self-Assembled Peptides: A New Generation of Vaccine Adjuvant Platform." Vaccines. 2025;13(12):1183. https://www.mdpi.com/2076-393X/13/12/1183

  19. "Supramolecular Peptide Self-Assemblies Facilitate Oral Immunization." ACS Biomaterials Science & Engineering. 2024. https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c00525

  20. "The employment of double-adjuvant nanoparticle to enhance immune responses for neoantigen vaccine." Nano Research. 2025. https://www.sciopen.com/article/10.26599/NR.2025.94907712

  21. Ren H, et al. "HydrogelFinder: A foundation model for rational design of self-assembling peptides." 2024. Referenced in Immuno. 2024;4(4):21. https://www.mdpi.com/2673-5601/4/4/21

  22. "Next-generation cancer vaccines: targeting cryptic and non-canonical antigens for precision immunotherapy." PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12464554/

  23. Bristol-Myers Squibb. BMS-986189 Phase I trial (NCT02739373). https://pubs.acs.org/doi/abs/10.1021/acs.joc.4c00430

  24. "Designing a multi-epitope universal vaccine for concurrent infections of SARS-CoV-2 and influenza viruses." BMC Infectious Diseases. 2025. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-11066-3